WO2009116061A3 - Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine - Google Patents

Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine Download PDF

Info

Publication number
WO2009116061A3
WO2009116061A3 PCT/IN2009/000009 IN2009000009W WO2009116061A3 WO 2009116061 A3 WO2009116061 A3 WO 2009116061A3 IN 2009000009 W IN2009000009 W IN 2009000009W WO 2009116061 A3 WO2009116061 A3 WO 2009116061A3
Authority
WO
WIPO (PCT)
Prior art keywords
atorvastatin
pharmaceutical composition
oral pharmaceutical
stable oral
pharmaceutically acceptable
Prior art date
Application number
PCT/IN2009/000009
Other languages
English (en)
Other versions
WO2009116061A2 (fr
Inventor
Senapati Manoj
Ranjan Manas
Agarwala Udit
V. Satyanarayana
Ashok Rampal
Original Assignee
Alkem Laboratories Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkem Laboratories Ltd. filed Critical Alkem Laboratories Ltd.
Publication of WO2009116061A2 publication Critical patent/WO2009116061A2/fr
Publication of WO2009116061A3 publication Critical patent/WO2009116061A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne une composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine ou son sel pharmaceutiquement acceptable et des sels d'aluminium alcalins en une quantité suffisante pour prévenir la dégradation de l'atorvastatine ou de son sel pharmaceutiquement acceptable.
PCT/IN2009/000009 2008-01-10 2009-01-05 Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine WO2009116061A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN78MU2008 2008-01-10
IN78/MUM/2008 2008-01-10

Publications (2)

Publication Number Publication Date
WO2009116061A2 WO2009116061A2 (fr) 2009-09-24
WO2009116061A3 true WO2009116061A3 (fr) 2009-12-17

Family

ID=41091324

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000009 WO2009116061A2 (fr) 2008-01-10 2009-01-05 Composition pharmaceutique stable, à usage oral, comprenant de l'atorvastatine

Country Status (1)

Country Link
WO (1) WO2009116061A2 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
WO2004010980A1 (fr) * 2002-07-25 2004-02-05 Novartis Ag Compositions renfermant des inhibiteurs de la reductase hmg-coa
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005115380A2 (fr) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Absorption regulee et localisee de statines dans le tractus gastro-intestinal aux fins de l'obtention de taux sanguins eleves de statines
WO2006070248A1 (fr) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016693A1 (fr) * 1993-01-19 1994-08-04 Warner-Lambert Company Formulation ci-981, orale, stable et son procede de preparation
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
WO2004010980A1 (fr) * 2002-07-25 2004-02-05 Novartis Ag Compositions renfermant des inhibiteurs de la reductase hmg-coa
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
WO2005115380A2 (fr) * 2004-05-27 2005-12-08 Dexcel Pharma Technologies Ltd Absorption regulee et localisee de statines dans le tractus gastro-intestinal aux fins de l'obtention de taux sanguins eleves de statines
WO2006070248A1 (fr) * 2004-12-28 2006-07-06 Ranbaxy Laboratories Limited Procedes permettant de preparer des formes posologiques pharmaceutiques solides et stables a base d'atorvastatine et d'amlodipine

Also Published As

Publication number Publication date
WO2009116061A2 (fr) 2009-09-24

Similar Documents

Publication Publication Date Title
AU2007299727A8 (en) Self preserved aqueous pharmaceutical compositions
EP2078731A4 (fr) Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
EP2130552A4 (fr) Composition pharmaceutique comportant un anticorps anti-grp 78 en tant qu'ingredient actif
WO2008006528A3 (fr) Nouvelles compositions pharmaceutiques comprenant du lévétiracétam
IL178425A0 (en) Carboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL190749A0 (en) Anti-misuse microparticulate oral pharmaceutical form
HK1127877A1 (en) Composition containing peptide as the active ingredient
WO2007146248A3 (fr) Préparations de laquinimod stables
EP2045253A4 (fr) DÉRIVÉ D'ACIDE alpha-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
IL181827A0 (en) Donepezil salts suitable for the preparation of pharmaceutical compositions
EP2100607A4 (fr) Composition pharmaceutique présentant une stabilité au stockage améliorée
SI2033629T1 (sl) Trden farmacevtski sestavek, ki obsega valsartan
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
EP2196206B8 (fr) Remède destiné à soulager des troubles cutanés comprenant un dérivé de morphinane ou l'un de ses sels d'addition d'acide acceptables sur le plan pharmacologique en tant que principe actif
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
WO2010055119A3 (fr) Composition pharmaceutique comprenant du pimobendane
EP1916251A4 (fr) Sels d érianine, leurs procédés de préparation et compositions pharmaceutiques contenant ceux-ci
WO2008003050A3 (fr) Formulations de nitrate de gallium
WO2010038091A3 (fr) Composition pharmaceutique a combinaison stable
EP2351754A4 (fr) Composé de phénanthroindolizidine et inhibiteur de nf b le contenant en tant que principe actif
WO2011135580A3 (fr) Compositions pharmaceutiques de sirolimus
WO2008020314A3 (fr) Formulations de dosage stabilisantes à base de statine
IL208151A0 (en) Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
EP1584335A3 (fr) Combinaison de substances actives comprenant un composé carbinol et un opioïde
ZA200901164B (en) Self preserved aqueous pharmaceutical compositions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09723084

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09723084

Country of ref document: EP

Kind code of ref document: A2